Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

I. Truxova, L. Kasikova, C. Salek, M. Hensler, D. Lysak, P. Holicek, P. Bilkova, M. Holubova, X. Chen, R. Mikyskova, M. Reinis, M. Kovar, B. Tomalova, JP. Kline, L. Galluzzi, R. Spisek, J. Fucikova

. 2020 ; 105 (7) : 1868-1878. [pub] 20191003

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020395

In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinical evidence indicates that danger signals play a crucial role in the (re-)activation of antitumor immune responses in vivo, thus having a major impact on patient prognosis. We have previously demonstrated that the presence of calreticulin on the surface of malignant blasts is a positive prognostic biomarker for patients with acute myeloid leukemia (AML). Calreticulin exposure not only correlated with enhanced T-cell-dependent antitumor immunity in this setting but also affected the number of circulating natural killer (NK) cells upon restoration of normal hematopoiesis. Here, we report that calreticulin exposure on malignant blasts is associated with enhanced NK cell cytotoxic and secretory functions, both in AML patients and in vivo in mice. The ability of calreticulin to stimulate NK-cells relies on CD11c+CD14high cells that, upon exposure to CRT, express higher levels of IL-15Rα, maturation markers (CD86 and HLA-DR) and CCR7. CRT exposure on malignant blasts also correlates with the upregulation of genes coding for type I interferon. This suggests that CD11c+CD14high cells have increased capacity to migrate to secondary lymphoid organs, where can efficiently deliver stimulatory signals (IL-15Rα/IL-15) to NK cells. These findings delineate a multipronged, clinically relevant mechanism whereby surface-exposed calreticulin favors NK-cell activation in AML patients.

000      
00000naa a2200000 a 4500
001      
bmc21020395
003      
CZ-PrNML
005      
20210830102111.0
007      
ta
008      
210728s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2019.223933 $2 doi
035    __
$a (PubMed)31582537
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Truxova, Iva $u Sotio, Prague, Czech Republic
245    10
$a Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients / $c I. Truxova, L. Kasikova, C. Salek, M. Hensler, D. Lysak, P. Holicek, P. Bilkova, M. Holubova, X. Chen, R. Mikyskova, M. Reinis, M. Kovar, B. Tomalova, JP. Kline, L. Galluzzi, R. Spisek, J. Fucikova
520    9_
$a In some settings, cancer cells responding to treatment undergo an immunogenic form of cell death that is associated with the abundant emission of danger signals in the form of damage-associated molecular patterns. Accumulating preclinical and clinical evidence indicates that danger signals play a crucial role in the (re-)activation of antitumor immune responses in vivo, thus having a major impact on patient prognosis. We have previously demonstrated that the presence of calreticulin on the surface of malignant blasts is a positive prognostic biomarker for patients with acute myeloid leukemia (AML). Calreticulin exposure not only correlated with enhanced T-cell-dependent antitumor immunity in this setting but also affected the number of circulating natural killer (NK) cells upon restoration of normal hematopoiesis. Here, we report that calreticulin exposure on malignant blasts is associated with enhanced NK cell cytotoxic and secretory functions, both in AML patients and in vivo in mice. The ability of calreticulin to stimulate NK-cells relies on CD11c+CD14high cells that, upon exposure to CRT, express higher levels of IL-15Rα, maturation markers (CD86 and HLA-DR) and CCR7. CRT exposure on malignant blasts also correlates with the upregulation of genes coding for type I interferon. This suggests that CD11c+CD14high cells have increased capacity to migrate to secondary lymphoid organs, where can efficiently deliver stimulatory signals (IL-15Rα/IL-15) to NK cells. These findings delineate a multipronged, clinically relevant mechanism whereby surface-exposed calreticulin favors NK-cell activation in AML patients.
650    _2
$a zvířata $7 D000818
650    12
$a kalretikulin $x genetika $x metabolismus $7 D037282
650    _2
$a cytotoxicita imunologická $7 D003602
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-15 $7 D019409
650    _2
$a buňky NK $7 D007694
650    12
$a akutní myeloidní leukemie $x terapie $7 D015470
650    _2
$a aktivace lymfocytů $7 D008213
650    _2
$a myši $7 D051379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Kasikova, Lenka $u Sotio, Prague, Czech Republic $u Department of Immunology, Charles University, 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Salek, Cyril $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Institute of Clinical and Experimental Hematology, 1 Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hensler, Michal $u Sotio, Prague, Czech Republic
700    1_
$a Lysak, Daniel $u Department of Hematology and Oncology, University Hospital in Pilsen, Czech Republic
700    1_
$a Holicek, Peter $u Sotio, Prague, Czech Republic $u Department of Immunology, Charles University, 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Bilkova, Pavla $u Sotio, Prague, Czech Republic
700    1_
$a Holubova, Monika $u Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Chen, Xiufen $u Department of Medicine, University of Chicago, Chicago, IL, USA
700    1_
$a Mikyskova, Romana $u Laboratory of Immunological and Tumour models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Reinis, Milan $u Laboratory of Immunological and Tumour models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kovar, Marek $u Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Tomalova, Barbora $u Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kline, Justin P $u Department of Medicine, University of Chicago, Chicago, IL, USA $u Committee on Immunology, University of Chicago, Chicago, IL, USA $u University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA $u Sandra and Edward Meyer Cancer Center, New York, NY, USA $u Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA $u Department of Dermatology, Yale School of Medicine, New Haven, CT, USA $u Universite de Paris, Paris, France
700    1_
$a Spisek, Radek $u Sotio, Prague, Czech Republic $u Department of Immunology, Charles University, 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Fucikova, Jitka $u Sotio, Prague, Czech Republic fucikova@sotio.com $u Department of Immunology, Charles University, 2 Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 105, č. 7 (2020), s. 1868-1878
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31582537 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102112 $b ABA008
999    __
$a ok $b bmc $g 1691048 $s 1140841
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 105 $c 7 $d 1868-1878 $e 20191003 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace